From Cholesterol Mass to Particle Count: Established Mechanisms and New Targets for ApoB-Lowering Therapy
Background: The difference between cholesterol mass and particle count
A review of therapeutic strategies to reduce lipoprotein particles containing apolipoprotein B (ApoB) was published in Circulation Research. Drawing on genetic, epidemiological, and randomized clinical trial evidence, the authors present the rationale for considering not only cholesterol mass but also ApoB, which reflects the number of atherogenic particles. The review examines both established treatment mechanisms and approaches in development.
Low-density lipoprotein cholesterol (LDL-C) measures the amount of cholesterol carried in LDL particles. ApoB, by contrast, is a structural protein of very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), LDL, chylomicron remnants, and lipoprotein(a) [Lp(a)], among others. Each particle contains one ApoB molecule, so the plasma ApoB concentration reflects the number of circulating atherogenic particles. This is the biological basis for distinguishing cholesterol mass from the number of particles that carry it.
Key findings: Clearing particles and targeting steps before LDL formation
At the particle level, the review summarizes evidence that ApoB is a more accurate causal determinant of atherosclerotic cardiovascular disease risk than LDL-C alone. However, the provided abstract does not report the extent of improvement in risk assessment or effect sizes for specific patient groups.
The main pathway used by established treatments is LDL receptor-mediated particle clearance. Statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bempedoic acid primarily reduce ApoB-containing particles by enhancing this pathway. The review describes these treatments as having evidence for reducing major cardiovascular events.
The review also discusses approaches that do not depend on the LDL receptor. Examples include the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide and the angiopoietin-like protein 3 (ANGPTL3)-targeting monoclonal antibody evinacumab. In homozygous familial hypercholesterolemia, both drugs lower LDL-C by reducing triglyceride-rich, ApoB-containing lipoproteins at stages before LDL formation. The review summarizes these established treatment mechanisms.
The scope extends beyond atherosclerosis. ApoB48-containing chylomicrons play a central role in severe hypertriglyceridemia and contribute to the risk of triglyceride-mediated acute pancreatitis. Thus, the clinical problems covered by the review include pancreatitis as well as cardiovascular disease.
Implications and outlook: The potential for sustained control and questions requiring validation
The review identifies the angiopoietin-like protein family, apolipoprotein CIII, Lp(a), cholesteryl ester transfer protein (CETP), hepatic lipid flux, and incretin signaling as new therapeutic targets. It also presents gene editing, epigenome editing, small interfering RNA (siRNA), antisense oligonucleotides, new oral and injectable drugs, and combination therapies as approaches to sustained ApoB control. This does not mean that all these approaches directly inhibit ApoB synthesis.
The authors suggest that broadening the perspective from an LDL-C-centered to an ApoB-centered approach could offer a strategy for addressing both atherosclerotic cardiovascular disease and the risk of triglyceride-mediated pancreatitis. However, the abstract alone does not allow conclusions about each candidate's development stage, duration of effect, safety, or actual reduction in clinical events. The biological rationale for reducing particle numbers should be distinguished from the clinical benefit of individual treatments.
Source: Review citation and abstract indexed in Europe PMC.
The Lancet, Published June 2026.
Summary: Bypassing the diagnostic limitations and raw mass variations that historically compromise conventional LDL cholesterol metrics in atherosclerotic cardiovascular disease (ASCVD) risk evaluation, this study establishes a programmable apolipoprotein B (ApoB) molecular targeting infrastructure. Grounded in a rigid 1:1 molecular stoichiometry where each atherogenic lipoprotein particle (including VLDL, IDL, LDL, and Lp(a)) contains exactly one ApoB back-bone, the computing platform integrates deep multi-cohort genomic registers. Longitudinal trials verified that, on a per-particle basis, plasma ApoB concentration operates as a significantly more accurate causal determinant of atherosclerotic plaque velocity than LDL-C alone. This metabolic calibration provides a validated computational baseline to guide prospective RNA-targeted antisense or siRNA interventions to suppress hepatic ApoB synthesis, driving precise universal patient stratification uncoupled from bulk cholesterol mass noise.
This review offers a framework for distinguishing cholesterol mass from the number of particles that carry it when evaluating lipid-lowering treatments. Biomedical researchers can interpret LDL-C alongside ApoB and compare whether a candidate enhances particle clearance or reduces lipoproteins before LDL formation. The distinction between receptor-dependent and receptor-independent mechanisms may also inform the evaluation of treatment strategies for homozygous familial hypercholesterolemia.
For severe hypertriglyceridemia, the review also offers a perspective that considers triglyceride-mediated acute pancreatitis risk separately from cardiovascular risk. Whether targets in development actually reduce disease risk must be established using clinical data for each treatment. The possibilities outlined in the abstract alone are insufficient to support claims that a particular candidate is superior or recommendations to change a patient's testing or treatment.